PRINCETON, N.J., Jan. 7 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that it will present at the 22nd Annual JPMorgan Healthcare Conference at 2:00 PM Eastern Standard Time on January 14, 2004. The conference is being held at The Westin St. Francis Hotel in San Francisco, CA. The Medarex presentation will be webcast live and will be available for replay for at least 14 days following the conference. The presentation can be accessed through the Webcasts page in the Investor Relations section of the Medarex website via the Internet at http://www.medarex.com/Investor/Webcasts.htm.
Medarex is a biopharmaceutical company focused on the discovery and development of therapeutics to treat life-threatening and debilitating diseases. Medarex’s UltiMAb Human Antibody Development System(R) is a unique combination of human antibody technologies that Medarex believes enables the rapid creation and development of fully human antibodies to a wide range of potential disease targets for therapeutic antibody products, including products for the treatment of cancer, inflammation, autoimmune and infectious diseases. Medarex’s product pipeline is based on a variety of therapeutic antibody products developed through the use of its UltiMAb(TM) technology. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP manufacturing services. For more information about Medarex, visit its website at http://www.medarex.com/.
Medarex(R), the Medarex logo, UltiMAb(TM) and UltiMAb Human Antibody Development System(R) are trademarks of Medarex, Inc. All rights are reserved.
Medarex, Inc.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, x221, bothof Medarex
Company News On-Call: http://www.prnewswire.com/comp/108265.html
